| |
News, Announcements & Awards
Announcements
Grant Merrill Featured in "Living the Biopharma Dream"
AES Director of Project Development, Grant Merrill, is featured in the Nov/Dec issue of Pharmaceutical Manufacturing for a recent turnkey project at the University of Nebraska.
Mr. Merrill led a multi-discipline design and construction team that was responsible for this 6,000 SF bioprocessing facility within a existing operational laboratory and classroom building. The project team delivered a functional cleanroom facility complete with its clean utility systems (WFI, clean steam, CIP/SIP) to support the development of vaccines and therapies from recombinant yeast and bacteria.
Learn more about the advantages of modular cleanroom technology to save time and money on your next cleanroom project.If you would like to schedule an appointment in advance, please contact us.
News Alert
Live Interview from ISPE Washington 2009
Montgomeryville, PA - November 15, 2008-Jameson Publishing has posted their interview with AES Director of Project Development, Grant Merrill, on their website.
Mr. Merrill answered their questions about the benefits of modular construction compared to dry-wall, focusing on finish details and schedule. We invite to listen to the interview here, or email Linda Jones, AES Marketing Communications Manager, for more information.
Listen to Cliff Satterfield, recently interviewed on the "Industry Today" webcast, to learn more about how AES can maximize your cleanroom investment! http://www.industrialinfo.com/podcasts/industrytoday/ind20090302.mp3
AES Celebrates Growth with New Factory
AES celebrated the official opening of its new 80,000 sq. ft. cleanroom manufacturing facility on October 16. The new facility houses manufacturing operations and product development for the AES Pharma System modular cleanroom system, and reinforces the company's commitment to supporting the life science and biotechnology industries with the advanced facilities they require for manufacturing their product in compliance with strict regulatory demands.
|
|
| |
|